Memphasys Limited (ASX: MEM) continues to expand its global footprint, with the announcement of utilisation testing for its Felix™ System at a facility owned by Jinxin Fertility Group Limited (HKEX: JXR), a leading provider of assisted reproductive services (ARS). This milestone reflects Memphasys’ strategic push into one of the largest and fastest-growing IVF markets worldwide.
Testing at a Leading ARS Provider
The utilisation testing is taking place at Sichuan Jinxin Xinan Women & Children Hospital in Chengdu, China, a key facility under the Jinxin Fertility Group. JXR is a renowned name in the ARS and women and children’s healthcare sectors, boasting over 70 years of medical expertise. As China’s largest private ARS provider and a major player in the US, JXR provides an ideal environment for evaluating the Felix™ System.
Since its listing on the Hong Kong Stock Exchange in 2019, JXR has expanded its global presence, managing six hospitals and five co-managed facilities in mainland China, alongside operations in Hong Kong, the US, and Laos. JXR’s emphasis on delivering integrated, high-quality reproductive services aligns with Memphasys’ mission to enhance outcomes in assisted reproduction.
Sichuan Jinxin Xinan Women & Children Hospital in Chengdu, China
Felix™ System Utilisation Testing: Key Details
The testing, led by Heranova Lifesciences HK Limited, involves 50 cases, covering both routine and challenging IVF scenarios. It will evaluate the Felix™ System’s ability to improve key sperm parameters, including motility, morphology, concentration, and DNA integrity. The test will also assess the system’s operational efficiency and usability for its high-volume IVF clinics.
Dr. David Ali, Managing Director & CEO of Memphasys, noted:
“Collaborating with a group of Jinxin’s stature provides invaluable further validation for the Felix™ System. This study is a critical step toward demonstrating the system’s benefits and suitability for the Chinese market, one of the largest ARS sectors globally.”
The utilisation testing aims to confirm the Felix™ System as a compelling option for clinics focused on improving biological outcomes while reducing operational costs.
Significance of the Chinese Market
China represents a massive opportunity for Memphasys, with its IVF market projected to grow from USD 5.37 billion in 2023 to USD 9.04 billion by 2030, at a CAGR of 7.7%. Factors such as delayed motherhood, rising infertility rates, and advancements in reproductive technologies are driving this growth. Collaborating with JXR provides Memphasys a foothold in this burgeoning sector, while leveraging JXR’s expertise and extensive network enhances the likelihood of regulatory and commercial success.
Momentum from Recent Achievements
This announcement builds on Memphasys’ December 2024 completion of a clinical trial for the Felix™ System in Australia. Conducted across nine Monash IVF sites, the trial is anticipated to confirm the system’s superior performance compared to traditional sperm preparation methods. The trial results are expected to support regulatory submissions, including CE Mark (Europe) TGA (Australia), CDSCO (India) and NMPA (China), while strengthening commercial discussions.
Further, Memphasys’ partnership with Heranova for Greater China underscores the importance of regional expertise. The Letter of Intent signed in December 2024 includes plans for local licensing, regulatory approvals, and expanded market penetration through Heranova’s network.
By collaborating with Heranova and Jinxin Fertility Group, Memphasys is strategically positioning the Felix™ System for success in China, one of the most dynamic ARS markets globally. The utilisation testing at JXR’s Sichuan facility not only highlights the system’s potential to enhance IVF outcomes, but also aligns Memphasys with a global leader in reproductive health.
As Memphasys builds on its clinical and commercial milestones, its partnership with JXR represents a key opportunity to scale its technology and transform assisted reproduction. Investors and stakeholders will keenly await the results of the testing, as well as further developments in Memphasys’ global expansion.
